Predictors of high sensitivity C-reactive protein levels in patients with systemic lupus erythematosus

Abstract

Despite the increased prevalence of cardiovascular disease in patients with systemic lupus erythematosus (SLE), little is known about the role of high sensitivity C-reactive protein (hsCRP) or whether ethnicity, gender, anthropometric measures and treatment can alter hsCRP levels. We evaluated the effects of treatment and demographic, anthropometric and socio-economic variables on hsCRP levels in SLE. High sensitivity C-reactive protein levels were measured using an immunoturbidimetric assay in 610 patients from the Hopkins Lupus Cohort, who were followed-up regularly. In stepwise multiple regression analyses, body mass index (BMI) [odds ratio (OR) 1.72, 95% confidence interval (CI) 1.34—2.20, P < 0.001], African-American ethnicity (OR 1.97, 95% CI 1.22—3.19, P < 0.01), education (OR 0.60, 95% CI 0.42—0.86, P < 0.01), statin use (OR 0.38, 95% CI 0.18—0.82, P < 0.05), estrogen use (OR 3.65, 95% CI 1.19—11.22, P < 0.05), SLE Disease Activity Index score (OR 1.76, 95% CI 1.09—2.87, P < 0.05) and cumulative prednisone dose (OR 1.27, 95% CI 1.01—1.60, P < 0.05) were significant predictors of hsCRP levels. These findings suggest that hsCRP levels should be adjusted for BMI, ethnicity, education level, disease activity and medications when conducting cardiovascular risk assessment in patients with lupus. Lupus (2008) 17, 114—123.

Keywords

cardiovascular risk factors C-reactive protein systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

Manzi S. , Meilahn EN , Rairie JE et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol 1997; 145: 408—415.

Abu-Shakra M. , Urowitz MB , Gladman DD , Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol 1995; 22: 1259—1264.

Petri M. , Perez-Gutthann S. , Spence D. , Hochberg MC Risk factors for coronary artery disease in patients with systemic lupus erythematosus . Am J Med 1992; 93: 513—519.

Pistiner M. , Wallace DJ , Nessim S. , Metzger AL , Klinenberg JR Lupus erythematosus in the 1980s: a survey of 570 patients. Semin Arthritis Rheum 1991; 21: 55—64.

Urowitz MB , Gladman DD Contributions of observational cohort studies in systemic lupus erythematosus: the university of toronto lupus clinic experience. Rheum Dis Clin North Am 2005; 31: 211—221, v.

Esdaile JM , Abrahamowicz M. , Grodzicky T. et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2331—2337.

Libby P. Inflammation in atherosclerosis. Nature 2002 ; 420: 868—874.

Pearson TA , Mensah GA , Alexander RW et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American heart association. Circulation 2003; 107: 499—511.

Danesh J. , Wheeler JG , Hirschfield GM et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387—1397.

10.

Ridker PM , Cushman M. , Stampfer MJ , Tracy RP , Hennekens CH Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973—979.

11.

Selzer F. , Sutton-Tyrrell K. , Fitzgerald SG et al. Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheum 2004; 50: 151—159.

12.

Roman MJ , Shanker BA , Davis A. et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399—2406.

13.

Asanuma Y. , Oeser A. , Shintani AK et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2407—2415.

14.

Svenungsson E. , Jensen-Urstad K. , Heimburger M. et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 104: 1887—1893.

15.

Manzi S. , Selzer F. , Sutton-Tyrrell K. et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 51—60.

16.

Toloza SM , Uribe AG , McGwin G. Jr et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004; 50: 3947—3957.

17.

Khera A. , McGuire DK , Murphy SA et al. Race and gender differences in C-reactive protein levels. J Am Coll Cardiol 2005; 46: 464—469.

18.

Albert MA , Glynn RJ , Buring J. , Ridker PM C-reactive protein levels among women of various ethnic groups living in the United States (from the women's health study). Am J Cardiol 2004; 93: 1238—1242.

19.

Rexrode KM , Pradhan A. , Manson JE , Buring JE , Ridker PM Relationship of total and abdominal adiposity with CRP and IL-6 in women. Ann Epidemiol 2003; 13: 674—682.

20.

Visser M. , Bouter LM , McQuillan GM , Wener MH , Harris TB Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999; 282: 2131—2135.

21.

Ridker PM , Cannon CP , Morrow D. et al. C-reactive protein levels and outcomes after statin therapy . N Engl J Med 2005; 352: 20—28.

22.

Oeser A. , Chung CP , Asanuma Y. , Avalos I. , Stein CM Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. Arthritis Rheum 2005; 52: 3651—3659.

23.

Becker GJ , Waldburger M. , Hughes GR , Pepys MB Value of serum C-reactive protein measurement in the investigation of fever in systemic lupus erythematosus. Ann Rheum Dis 1980; 39: 50—52.

24.

Honig S. , Gorevic P. , Weissmann G. C-reactive protein in systemic lupus erythematosus. Arthritis Rheum 1977; 20: 1065—1070.

25.

Petri M. Hopkins lupus cohort. 1999 update. Rheum Dis Clin North Am 2000; 26: 199—213, v.

26.

Tan EM , Cohen AS , Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271—1277.

27.

Petri M. , Hellmann D. , Hochberg M. Validity and reliability of lupus activity measures in the routine clinic setting. J Rheumatol 1992; 19: 53—59.

28.

Petri M. , Buyon J. , Kim M. Classification and definition of major flares in SLE clinical trials. Lupus 1999; 8: 685—691.

29.

Petri M. , Howard D. , Repke J. Frequency of lupus flare in pregnancy. The Hopkins lupus pregnancy center experience. Arthritis Rheum 1991; 34: 1538—1545.

30.

Buyon JP , Petri MA , Kim MY et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005; 142: 953—962.

31.

Petri M. , Genovese M. Incidence of and risk factors for hospitalizations in systemic lupus erythematosus: a prospective study of the Hopkins lupus cohort. J Rheumatol 1992; 19: 1559—1565.

32.

Ford ES , Giles WH , Myers GL , Mannino DM Population distribution of high-sensitivity C-reactive protein among US men: findings from national health and nutrition examination survey 1999—2000 . Clin Chem 2003; 49: 686—690.

33.

Ford ES , Giles WH , Mokdad AH , Myers GL Distribution and correlates of C-reactive protein concentrations among adult US women. Clin Chem 2004; 50: 574—581.

34.

Barinas-Mitchell E. , Cushman M. , Meilahn EN , Tracy RP , Kuller LH Serum levels of C-reactive protein are associated with obesity, weight gain, and hormone replacement therapy in healthy postmenopausal women. Am J Epidemiol 2001; 153: 1094—1101.

35.

Pankow JS , Folsom AR , Cushman M. et al. Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study. Atherosclerosis 2001; 154: 681—689.

36.

Szalai AJ , McCrory MA , Cooper GS , Wu J. , Kimberly RP Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene. Genes Immun 2002; 3: 14—19.

37.

Papanicolaou DA , Wilder RL , Manolagas SC , Chrousos GP The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998; 128: 127—137.

38.

Wyatt SB , Winters KP , Dubbert PM Overweight and obesity: prevalence, consequences, and causes of a growing public health problem. Am J Med Sci 2006; 331: 166—174.

39.

Field AE , Coakley EH , Must A. et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 2001 ; 161: 1581—1586.

40.

Bucher HC , Ragland DR Socioeconomic indicators and mortality from coronary heart disease and cancer: a 22-year follow-up of middle-aged men. Am J Public Health 1995; 85: 1231—1236.

41.

Koster A. , Bosma H. , Penninx BW et al. Association of inflammatory markers with socioeconomic status . J Gerontol A Biol Sci Med Sci 2006; 61: 284—290.

42.

Panagiotakos DB , Pitsavos CE , Chrysohoou CA et al. The association between educational status and risk factors related to cardiovascular disease in healthy individuals: The ATTICA study. Ann Epidemiol 2004; 14: 188—194.

43.

Owen N. , Poulton T. , Hay FC , Mohamed-Ali V. , Steptoe A. Socioeconomic status, C-reactive protein, immune factors, and responses to acute mental stress. Brain Behav Immun 2003 ; 17: 286—295.

44.

Jousilahti P. , Salomaa V. , Rasi V. , Vahtera E. , Palosuo T. Association of markers of systemic inflammation, C reactive protein, serum amyloid A, and fibrinogen, with socioeconomic status . J Epidemiol Community Health 2003; 57: 730—733.

45.

Marmot MG , Smith GD , Stansfeld S. et al. Health inequalities among British civil servants: the Whitehall II study. Lancet 1991; 337: 1387—1393.

46.

Frohlich M. , Sund M. , Lowel H. , Imhof A. , Hoffmeister A. , Koenig W. Independent association of various smoking characteristics with markers of systemic inflammation in men. Results from a representative sample of the general population (MONICA Augsburg Survey 1994/95). Eur Heart J 2003; 24: 1365—1372.

47.

Imhof A. , Froehlich M. , Brenner H. , Boeing H. , Pepys MB , Koenig W. Effect of alcohol consumption on systemic markers of inflammation. Lancet 2001; 357: 763—767.

48.

Kaplan GA , Keil JE Socioeconomic factors and cardiovascular disease: a review of the literature . Circulation 1993; 88: 1973—1998.

49.

Pepys MB , Lanham JG , De Beer FC C-reactive protein in SLE. Clin Rheum Dis 1982; 8: 91—103.

50.

Pereira Da Silva JA , Elkon KB , Hughes GR , Dyck RF , Pepys MB

C-reactive protein levels in systemic lupus erythematosus: a classification criterion?

Arthritis Rheum 1980; 23: 770—771.

51.

Mochizuki T. , Aotsuka S. , Satoh T. Clinical and laboratory features of lupus patients with complicating pulmonary disease. Respir Med 1999; 93: 95—101.

52.

Moutsopoulos HM , Mavridis AK , Acritidis NC , Avgerinos PC High C-reactive protein response in lupus polyarthritis. Clin Exp Rheumatol 1983; 1: 53—55.

53.

Wais T. , Fierz W. , Stoll T. , Villiger PM Subclinical disease activity in systemic lupus erythematosus: immunoinflammatory markers do not normalize in clinical remission. J Rheumatol 2003; 30: 2133—2139.

54.

Liou LB Serum and in vitro production of IL-1 receptor antagonist correlate with C-reactive protein levels in newly diagnosed, untreated lupus patients. Clin Exp Rheumatol 2001; 19: 515—523.

55.

Ridker PM , Rifai N. , Clearfield M. et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959—1965.

56.

Balk EM , Lau J. , Goudas LC et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann Intern Med 2003; 139: 670—682.

57.

Kwak B. , Mulhaupt F. , Myit S. , Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399—1402.

58.

Bassuk SS , Rifai N. , Ridker PM High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol 2004; 29: 439—493.

59.

Ridker PM , Rifai N. , Rose L. , Buring JE , Cook NR Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557—1565.

60.

van Rooijen M. , Hansson LO , Frostegard J. , Silveira A. , Hamsten A. , Bremme K. Treatment with combined oral contraceptives induces a rise in serum C-reactive protein in the absence of a general inflammatory response. J Thromb Haemost 2006; 4: 77—82.

61.

Cushman M. , Legault C. , Barrett-Connor E. et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the postmenopausal estrogen/progestin interventions (PEPI) study . Circulation 1999; 100: 717—722.

62.

Manson JE , Hsia J. , Johnson KC et al. Estrogen plus progestin and the risk of coronary heart disease . N Engl J Med 2003; 349: 523—534.

63.

Pradhan AD , Manson JE , Rossouw JE et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 2002; 288: 980—987.

64.

Vongpatanasin W. , Tuncel M. , Wang Z. , Arbique D. , Mehrad B. , Jialal I. Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women . J Am Coll Cardiol 2003; 41: 1358—1363.

65.

Rubin LA , Urowitz MB , Gladman DD Mortality in systemic lupus erythematosus: the bimodal pattern revisited. Q J Med 1985; 55: 87—98.

66.

Zonana-Nacach A. , Barr SG , Magder LS , Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000; 43: 1801—1808.

67.

Bruce IN , Urowitz MB , Gladman DD , Hallett DC Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol 1999; 26: 2137—2143.

68.

Rahman P. , Gladman DD , Urowitz MB , Yuen K. , Hallett D. , Bruce IN The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol 1999; 26: 325—330.

69.

Wallace DJ , Metzger AL , Stecher VJ , Turnbull BA , Kern PA Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990; 89: 322—326.

70.

Barnes EV , Narain S. , Naranjo A. et al. High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus 2005; 14: 576—582.